Chronic pain
Conditions
Interventions
Trade Name: Ketamine
Product Name: ketamine
Product Code: RVG 22550
Pharmaceutical Form: Concentrate and solvent for concentrate for solution for infusion
Trade Name: Sodium Nitroprusside
Product Nam
Sponsors
LUMC
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects of either sex (10 men/10 women), aged 18-39 years with a body mass index =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Severe medical disease including hypertension, liver/renal disease, neurological disorders, diaphragmatic hernia/pyrosis; (history of) psychiatric or neurological disease; pregnancy/lactation; allergy to study medication; (history of) illicit drug use/alcoholism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the ability of NNP to prevent ketamine's psychotypical side effects;Secondary Objective: To assess pain relief from ketamine during NNP infusion;Primary end point(s): Psychedelic and negative effects are measured using visual analog scales ranging from 0 (no effect) to 10 cm (maximum effect) of the Bowdle and Bond & Ladder questionnaires;Timepoint(s) of evaluation of this end point: 15 min intervals during ketamine infusion | — |
Secondary
| Measure | Time frame |
|---|---|
| Timepoint(s) of evaluation of this end point: 15 min intervals during ketamine infusion;Secondary end point(s): Response to pressure pain, electrical pain and heat pain | — |
Countries
Netherlands
Contacts
Public ContactMonique van Velzen
LUMC
Outcome results
None listed